| |
| Magyar Kardiológusok Társasága |
|
| Congress of Cardiovascular Prevention in Pre-Elderly and Elderly Individuals |
 Rendezvény kezdete: 2016.06.30. | Rendezvény vége: 2016.07.02. |
| Helyszín: Szlovákia, Bratislava, |
| A rendezvény Web oldala: http://www.cardioelderly.org |
| First Congress of Cardiovascular Prevention in Pre-Elderly and Elderly Individuals (CPPEI 2016), June 30 – July 2, 2016 in Bratislava, Slovakia will bring together leading physicians, as well as industry experts to discuss the latest developments in Lipid Lowering Therapy, Antihypertensive Therapy, Atherogenic Dyslipidemia and more. |
|
|
 |
| |
| Magyar Immunológiai Társaság |
|
| DC2012 - 12th International Symposium on Dendritic Cells |
| Rendezvény kezdete: 2012.10.07. | Rendezvény vége: 2012.10.11. |
| Munkahely neve: DC 2012 Secretariat |
| Címe: 1F Haeoreum B/D 748-5 Yeoksam-dong
Gangnam-gu Seoul 135-925 Korea |
| Tel: +82-2-577-8422,8423 |
| Fax: +82-2-566-6087 |
| E-mail: dc@people-x.com |
| Helyszín: Korea, Daegu, EXCO Convention Center |
| A rendezvény Web oldala: http://www.dc2012.kr/ |
The 12th International Symposium on Dendritic Cells
The DC2012 is hosted by the Korean Association of Immunologists and organized by the
Organizing Committee of the DC 2012.
The DC 2012 is anticipating more than 1,600 participants and industry representatives from 40
different countries. I truly believe that DC2012 would be the milestone for all of us to understand the
cutting-edge of research trends, to share valuable information and to build a network between
specialists in the field of dendritic cells.
Deadline of Abstract Submission is extended to June 30, 2012
re-registration: Extended to Sep. 14th, 2012!
Clinical Trial Satellite Meeting(Sponsored by JW CreaGene, BD)
*Date & Time: October 8~9, 2012 / 12:20~13:20
*Venue: 4F Auditorium, EXCO
*Confirmed Speakers:
1)TriMix Dentritic cell therapy in Melanoma - the Brussels`s experience
-Prof. Thielemans Kris (Vrije Universiteit Brussel, Belgium)
2)Applying Lessons learned from Provenge to the development of new immunotherapies for cancer
-Dr. James B. Trager (Dendreon Corporation, USA)
-The lunch will be served during the Clinical Trial Satellite Meeting.
-Maximum 300 persons can attend the meeting on a first-come, first-served basis. |
|
|
|
